Get the Stockscreener App
0.2946
10.92%
-0.0361
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Prophase Labs Inc stock is traded at $0.2946, with a volume of 786.49K.
It is down -10.92% in the last 24 hours and up +22.75% over the past month.
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.
See More
Previous Close:
$0.3307
Open:
$0.3268
24h Volume:
786.49K
Relative Volume:
0.08
Market Cap:
$14.67M
Revenue:
$62.71M
Net Income/Loss:
$-10.48M
P/E Ratio:
-0.4676
EPS:
-0.63
Net Cash Flow:
$-13.77M
1W Performance:
-15.90%
1M Performance:
+22.75%
6M Performance:
-85.84%
1Y Performance:
-94.56%
1-Day Range:
$0.2943
$0.3336
1-Week Range:
$0.2943
$0.3551
52-Week Range:
$0.2179
$5.62
Prophase Labs Inc Stock (PRPH) Company Profile
Name
Prophase Labs Inc
Sector
Industry
Phone
(215) 345-0919
Address
711 STEWART AVE, SUITE 200, NEW YORK, PA
Compare PRPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRPH
Prophase Labs Inc
|
0.2946 | 14.67M | 62.71M | -10.48M | -13.77M | -0.63 |
|
TMO
Thermo Fisher Scientific Inc
|
422.27 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.40 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
475.07 | 34.90B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
108.37 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
152.30 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
Prophase Labs Inc Stock (PRPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-13-21 | Downgrade | Dawson James | Buy → Neutral |
| Jan-20-21 | Initiated | Dawson James | Buy |
Prophase Labs Inc Stock (PRPH) Latest News
Geode Capital Management LLC Boosts Stake in ProPhase Labs, Inc. (NASDAQ:PRPH) - Defense World
ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2024 Earnings Call Transcript - MSN
PRPH’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
There is no doubt that ProPhase Labs Inc (PRPH) ticks all the boxes. - Sete News
Metric Analysis: ProPhase Labs Inc (PRPH)’s Key Ratios in the Limelight - DWinneX
What was ProPhase Labs Inc (PRPH)’s performance in the last session? - uspostnews.com
Press Release Distribution & PR Platform - ACCESS Newswire
ProPhase Labs Inc (PRPH) is a good investment, but the stock may be overvalued - uspostnews.com
Daily Market Movement: ProPhase Labs Inc (PRPH) Sees a 0.54 Increase, Closing at 0.35 - DWinneX
Monitoring ProPhase Labs Inc (PRPH) after recent insider movements - knoxdaily.com
ProPhase Labs Inc (PRPH) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Investors Take Advantage Of 7.67% Gain In ProPhase Labs Inc (NASDAQ: PRPH) - Stocksregister
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Up 50.0% in March - Defense World
ProPhase Labs Closes $23.6M Asset Sale to Streamline Business Strategy - citybuzz -
ProPhase Labs Inc (NASDAQ: PRPH): Forecast Weak In 2025, Up -95.29% - Stocksregister
HighTower Advisors LLC Acquires 57,736 Shares of ProPhase Labs, Inc. (NASDAQ:PRPH) - Defense World
ProPhase Labs Inc (PRPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Challenges By GuruFocus - Investing.com Canada
ProPhase Labs Inc (PRPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Challenges - Yahoo Finance
A Tale of Resilience: ProPhase Labs Inc Amid Stock Market Turbulence - investchronicle.com
ProPhase Labs Inc (PRPH) Q4 2024 Earnings Call Highlights: Strat - GuruFocus
ProPhase Labs Delays Yearly Report Filing - TipRanks
Prophase Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ProPhase Labs, Inc. SEC 10-K Report - TradingView
ProPhase Labs Reports 2024 Financial Results and Strategic Shift - TipRanks
Earnings call transcript: ProPhase Labs Q4 2024 earnings miss, stock falls - Investing.com Australia
ProPhase Labs earnings missed by $1.62, revenue topped estimates - Investing.com Canada
Earnings call transcript: ProPhase Labs Q4 2024 earnings miss, stock falls By Investing.com - Investing.com Canada
ProPhase Labs Inc Reports $6.8 Million Revenue and $(2.61) EPS f - GuruFocus
ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024 - The Manila Times
ProPhase Labs Pivots Business Model After $53M Loss: Cancer Test Launch Takes Center Stage - Stock Titan
ProPhase Labs (PRPH) Set to Announce FY Earnings, Faces Challenges - GuruFocus.com
An Overview of ProPhase Labs's Earnings - Benzinga
ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025 - The Manila Times
ProPhase Labs Announces Key Full Year 2024 Financial Results PresentationVirtual Access Available - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ProPhase Labs (PRPH) Projected to Post Earnings on Thursday - Defense World
ProPhase Labs, Inc. CEO Ted Karkus to Present at Q1 Investor Summit Virtual on March 11th - Nasdaq
ProPhase Labs to Present at the Investor Summit Virtual on March 11 - GlobeNewswire
Can ProPhase Labs Convince Investors? CEO Reveals Strategic Vision Next Week - StockTitan
Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now - Yahoo Finance
ProPhase Labs, Inc. to Host Earnings Call - ACCESS Newswire
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH) - EIN News
Deeper Dive: Understanding ProPhase Labs Inc (PRPH) Through its Various Ratios - The Dwinnex
ProPhase Labs Examines Strategic Opportunities to Leverage - GlobeNewswire
ProPhase Labs Focuses On Telehealth And DTC Marketing For Prescription Drug Growth Strategy - Nasdaq
ProPhase Labs examines opportunities to leverage DTC multi-media infrastructure - TipRanks
ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs - The Manila Times
Can ProPhase's Telehealth Pivot Save Its Stock From Delisting? Company Says No Reverse Split Needed - StockTitan
ProPhase Labs (NASDAQ:PRPH) Now Covered by Analysts at StockNews.com - Defense World
Prophase Labs Inc Stock (PRPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):